miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2

Ovarian cancer is the most aggressive female reproductive tract tumours. Taxane (paclitaxel; TX) is widely used for ovarian cancer treatment. However, ovarian cancers often acquire chemoresistance. MicroRNAs (miR) have been reported to mediate many tumours’chemoresistance. We investigated the role o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Mohamed, Zeinab, Hassan, Mohamed Kamel, Okasha, Safwat, Mitamura, Takashi, Keshk, Sarah, Konno, Yusuke, Kato, Tatsuya, EL-Khamisy, Sherif F., Ohba, Yusuke, Watari, Hidemichi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2018
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6059020/
https://ncbi.nlm.nih.gov/pubmed/30046387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25698
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller